Related Experiment Videos
Association Between Ergot-Derived Dopamine Agonists and Valvular Heart Disease: A Systematic Review and Meta-Analysis
Amer Hammad1, Sindhura Ananthaneni2, Own Khraisat3
1From the Internal Medicine Department, Banner - University Medical Center Tucson, Tucson, AZ.
Cardiology in Review
|July 9, 2026
Summary
Ergot-derived dopamine agonists (DAs) significantly increase the risk of valvular heart disease (VHD). Patients using these drugs, especially long-term, require close echocardiographic monitoring for VHD development.
Area of Science:
- Cardiology
- Pharmacology
- Epidemiology
Background:
- Dopamine agonists (DAs) are used to treat Parkinson disease and hyperprolactinaemia.
- A potential link between DA use and valvular heart disease (VHD) has been suggested, but findings are inconsistent.
- Ergot-derived DAs, specifically, warrant investigation due to their chemical structure.
Purpose of the Study:
- To systematically review and meta-analyze the association between ergot-derived dopamine agonists (DAs) and the incidence of valvular heart disease (VHD).
- To evaluate the risk of developing VHD or worsening existing valvular regurgitation in patients treated with ergot-derived DAs compared to non-ergot DAs or controls.
Main Methods:
- A systematic review and meta-analysis of observational studies and clinical trials.
- Inclusion criteria: patients with Parkinson disease or hyperprolactinaemia treated with DAs.
- Pooled risk estimates were calculated using random-effects models, analyzing VHD incidence and specific valve regurgitation risks.
Main Results:
- Analysis of 47,270 patients from 33 studies revealed a higher VHD rate (4.0%) in ergot-derived DA users versus 1.1% in others.
- Significantly elevated pooled risk ratios for VHD were observed with pergolide, cabergoline, and bromocriptine.
- Ergot-derived DAs were linked to increased risk of aortic, mitral, and tricuspid regurgitation.
Conclusions:
- Ergot-derived dopamine agonists are significantly associated with an increased risk of valvular heart disease.
- Close echocardiographic monitoring is recommended for patients on ergot-derived DAs, particularly with long-term or high-dose therapy.
- Further research may explore mechanisms and non-ergot DA safety profiles.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...